deltatrials
Completed PHASE2 NCT00046787

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer

Sponsor: Astellas Pharma Inc

Conditions Carcinoma, Small Cell SCLC
Interventions OSI-211 (Liposomal Lurtotecan)
Updated 7 times since 2017 Last updated: Oct 18, 2011 Started: Sep 30, 2002 Completion: Feb 28, 2003

Listed as NCT00046787, this PHASE2 trial focuses on Carcinoma, Small Cell and SCLC and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 7 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Astellas Pharma Inc
  • OSI Pharmaceuticals
Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Aberdeen, United Kingdom
  • • Bebington, United Kingdom
  • • Denver, United States
  • • Knoxville, United States
  • • London, United Kingdom
  • • Manchester, United Kingdom
  • • Nashville, United States
  • • Newcastle upon Tyne, United Kingdom
  • • Nottingham, United Kingdom
  • • Tucson, United States